Crinetics Pharmaceuticals/$CRNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Ticker
$CRNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
437
ISIN
US22663K1079
Website
CRNX Metrics
BasicAdvanced
$2.9B
-
-$3.82
0.32
-
Price and volume
Market cap
$2.9B
Beta
0.32
52-week high
$59.95
52-week low
$24.10
Average daily volume
889K
Financial strength
Current ratio
22.527
Quick ratio
22.359
Long term debt to equity
3.504
Total debt to equity
4.053
Management effectiveness
Return on assets (TTM)
-20.13%
Return on equity (TTM)
-30.84%
Valuation
Price to revenue (TTM)
3,453.27
Price to book
2.28
Price to tangible book (TTM)
2.28
Price to free cash flow (TTM)
-9.891
Growth
Revenue change (TTM)
-61.50%
Earnings per share change (TTM)
1.40%
3-year revenue growth (CAGR)
-43.48%
3-year earnings per share growth (CAGR)
10.37%
What the Analysts think about CRNX
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
CRNX Financial Performance
Revenues and expenses
CRNX Earnings Performance
Company profitability
CRNX News
AllArticlesVideos
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
GlobeNewsWire·1 week ago
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
GlobeNewsWire·2 weeks ago
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $2.9B as of May 30, 2025.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of May 30, 2025.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.